Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice

Schreiber, Karen; Frishman, Margreta; Russell, Mark; Dey, Mrinalini; Flint, Julia; Allen, Alexander; Crossley, Amy; Gayed, Mary; Hodson, Kenneth; Khamashta, Munther A.; Moore, L.A.; Panchal, Sonia; Piper, Madeleine; Reid, Clare; Saxby, Katherine; Senvar, Naz; Tosounidou, Sofia; Venne, Maud van de; Warburton, Louise; Williams, David; Yee, Chee-Seng; Gordon, Caroline; Giles, Ian

doi:10.1093/rheumatology/keac559

Cited by 5 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct oral anticoagulants like rivaroxaban, apixaban, and dabigatran are utilized for secondary prevention of venous thromboembolism (VTE), although these medications are teratogenic. In pregnant women, accepted treatments include low-molecular-weight heparin (LMWH) and low-dose aspirin [4,[50][51][52].…”

Section: Treatment Options In Apsmentioning

confidence: 99%

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions

Mitranovici,

Chiorean,

Moraru

et al. 2024

JCM

View full text Add to dashboard Cite

Preeclampsia (PE) is a hypertensive disorder in pregnancy associated with significant fetal and maternal complications. Antiphospholipid syndrome (APS) is an acquired form of thrombophilia characterized by recurrent venous or arterial thrombosis and obstetric complications that significantly increases morbidity and mortality rates. While preeclampsia may not be the most prevalent obstetric complication in APS, it significantly impacts the long-term health of both mother and child. The treatment of preeclampsia in antiphospholipid syndrome is different from the treatment of preeclampsia as an independent disease. Despite current treatments involving anticoagulants, antiplatelet agents, and antihypertensive drugs, obstetric complications may persist, underscoring the need for cohesive management and effective treatments. The objective of our review is to briefly present knowledge about the physiopathology of preeclampsia and the role of antiphospholipid antibodies in this process. Based on the existing literature, our review aims to identify future directions in molecular pathology toward the discovery of biomarkers and targeted treatments. The application of multidisciplinary approaches and prognostic models, including new biomarkers, could be beneficial in the prediction of PE.

show abstract

Section: Treatment Options In Apsmentioning

confidence: 99%

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions

Mitranovici,

Chiorean,

Moraru

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Urate-lowering agents do not have clinically relevant negative effects on sperm quality and reproductive hormones in men with gout: a prospective open-label cohort study

Li,

Wang,

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Mercer,

Abhishek,

Kavirayani

et al. 2024

Rheumatology Advances in Practice

View full text Add to dashboard Cite

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology’s ‘Creating clinical guidelines: our protocol’, updated 2023.

show abstract

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice

Abstract: NICE has accredited the process used by BSR to create its clinical guidelines. The term began on 27 February 2012 and the current renewed accreditation is valid until 31 December 2023. More information on accreditation can be viewed at www.nice.org.uk/accreditation.

Cited by 5 publications

References 61 publications

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions

Urate-lowering agents do not have clinically relevant negative effects on sperm quality and reproductive hormones in men with gout: a prospective open-label cohort study

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Contact Info

Product

Resources

About